A prospective randomised open- label blinded-endpoint (PROBE) trial comparing telmisartan (MICARDIS) (40-80-80mg QD) and ramipril (2.5-5-10mg QD) in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring

Trial Profile

A prospective randomised open- label blinded-endpoint (PROBE) trial comparing telmisartan (MICARDIS) (40-80-80mg QD) and ramipril (2.5-5-10mg QD) in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2009

At a glance

  • Drugs Ramipril; Telmisartan
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms PRISMA
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 01 Sep 2009 Results of pooled analysis of PRISMA I and II published in the Journal of Human Hypertension.
    • 03 Dec 2008 Last checked against ClinicalTrials.gov record.
    • 28 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top